Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer

  • Authors:
    • Naomi Urano
    • Yoshiyuki Fujiwara
    • Yuichiro Doki
    • S. J. Kim
    • Yasuo Miyoshi
    • Shinzaburo Noguchi
    • Hiroshi Miyata
    • Shuji Takiguchi
    • Takushi Yasuda
    • Masahiko Yano
    • Morito Monden
  • View Affiliations

  • Published online on: February 1, 2006     https://doi.org/10.3892/ijo.28.2.375
  • Pages: 375-381
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Docetaxel, one of the most effective anticancer drugs for gastric cancer, targets β-tubulin, the major protein in mitotic spindles. Eight isotypes of β-tubulin, with tissue and organ-specific expression, have been identified in mammalian cells. We examined class III β-tubulin expression in gastric cancer and assessed its relationship with sensitivity to docetaxel-based chemotherapy. A total of 115 paraffin-embedded gastric tumors were analyzed by immunohistochemistry for class III β-tubulin expression. Twenty patients with advanced gastric cancer received preoperative docetaxel-based chemotherapy. Their biopsied specimens, obtained by endoscopy before chemotherapy were examined for class III β-tubulin expression. The relationship between expression and chemosensitivity was assessed. Forty-two (36.4%) of 115 cases were confirmed to be positive for class III β-tubulin expression. There was no association between clinicopathological status and prognosis. Among the patients positive for class III β-tubulin expression, only 16.7% showed no response to chemotherapy, while 64.3% responded to the chemotherapy in the negative group. Our results suggest that class III β-tubulin is a simple and useful predictive marker for the clinical response to docetaxel-based chemotherapy in gastric cancer.

Related Articles

Journal Cover

February 2006
Volume 28 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Urano N, Fujiwara Y, Doki Y, Kim SJ, Miyoshi Y, Noguchi S, Miyata H, Takiguchi S, Yasuda T, Yano M, Yano M, et al: Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 28: 375-381, 2006
APA
Urano, N., Fujiwara, Y., Doki, Y., Kim, S.J., Miyoshi, Y., Noguchi, S. ... Monden, M. (2006). Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. International Journal of Oncology, 28, 375-381. https://doi.org/10.3892/ijo.28.2.375
MLA
Urano, N., Fujiwara, Y., Doki, Y., Kim, S. J., Miyoshi, Y., Noguchi, S., Miyata, H., Takiguchi, S., Yasuda, T., Yano, M., Monden, M."Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer". International Journal of Oncology 28.2 (2006): 375-381.
Chicago
Urano, N., Fujiwara, Y., Doki, Y., Kim, S. J., Miyoshi, Y., Noguchi, S., Miyata, H., Takiguchi, S., Yasuda, T., Yano, M., Monden, M."Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer". International Journal of Oncology 28, no. 2 (2006): 375-381. https://doi.org/10.3892/ijo.28.2.375